SG11201811831SA - Compositions and methods for stabilizing flaviviruses with improved formulations - Google Patents
Compositions and methods for stabilizing flaviviruses with improved formulationsInfo
- Publication number
- SG11201811831SA SG11201811831SA SG11201811831SA SG11201811831SA SG11201811831SA SG 11201811831S A SG11201811831S A SG 11201811831SA SG 11201811831S A SG11201811831S A SG 11201811831SA SG 11201811831S A SG11201811831S A SG 11201811831SA SG 11201811831S A SG11201811831S A SG 11201811831SA
- Authority
- SG
- Singapore
- Prior art keywords
- urea
- sucrose
- trehalose
- msg
- alanine
- Prior art date
Links
- 241000710831 Flavivirus Species 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title 2
- 238000009472 formulation Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 230000000087 stabilizing effect Effects 0.000 title 1
- 230000002238 attenuated effect Effects 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662370611P | 2016-08-03 | 2016-08-03 | |
| PCT/US2017/045375 WO2018027075A1 (en) | 2016-08-03 | 2017-08-03 | Compositions and methods for stabilizing flaviviruses with improved formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811831SA true SG11201811831SA (en) | 2019-01-30 |
Family
ID=59593235
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811831SA SG11201811831SA (en) | 2016-08-03 | 2017-08-03 | Compositions and methods for stabilizing flaviviruses with improved formulations |
| SG10201913040SA SG10201913040SA (en) | 2016-08-03 | 2017-08-03 | Compositions and methods for stabilizing flaviviruses with improved formulations |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913040SA SG10201913040SA (en) | 2016-08-03 | 2017-08-03 | Compositions and methods for stabilizing flaviviruses with improved formulations |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10835597B2 (OSRAM) |
| EP (1) | EP3493839A1 (OSRAM) |
| JP (2) | JP7280179B2 (OSRAM) |
| KR (2) | KR20230132887A (OSRAM) |
| CN (1) | CN109789200A (OSRAM) |
| AU (2) | AU2017305498B2 (OSRAM) |
| CA (1) | CA3030343A1 (OSRAM) |
| CO (1) | CO2019001448A2 (OSRAM) |
| MX (2) | MX2019001473A (OSRAM) |
| PH (1) | PH12019500003A1 (OSRAM) |
| SG (2) | SG11201811831SA (OSRAM) |
| TW (2) | TW202309276A (OSRAM) |
| WO (1) | WO2018027075A1 (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104984357B (zh) * | 2015-06-02 | 2018-01-30 | 长春百克生物科技股份公司 | 不含明胶的疫苗保护剂组合物及流感减毒活疫苗 |
| GEAP202315128A (en) * | 2016-12-23 | 2023-02-10 | Serum Institute Of India Pvt Ltd | Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof |
| US20200390877A1 (en) | 2017-12-07 | 2020-12-17 | Merck Sharp & Dohme Corp. | Formulations of dengue virus vaccine compositions |
| US11738075B2 (en) | 2018-03-20 | 2023-08-29 | National Research Council Of Canada | Method for lyophilizing live vaccine strains of Francisella tularensis |
| KR102649069B1 (ko) | 2018-05-31 | 2024-03-19 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 안면 홍조 개선용 조성물 |
| WO2020027466A1 (ko) | 2018-07-28 | 2020-02-06 | 주식회사 엑소코바이오 | 엑소좀의 동결건조 방법 |
| KR102163806B1 (ko) | 2018-07-30 | 2020-10-07 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물 |
| US11464815B2 (en) * | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
| AU2019393877A1 (en) * | 2018-12-05 | 2021-06-17 | Seres Therapeutics, Inc. | Compositions for stabilizing bacteria and uses thereof |
| MX2022001742A (es) | 2019-08-16 | 2022-04-07 | Takeda Vaccines Inc | Metodos para prevenir el dengue y la hepatitis a. |
| EP4110381A1 (en) * | 2020-02-27 | 2023-01-04 | Takeda Vaccines, Inc. | Method for removing host cell dna from virus preparation |
| CN115023135B (zh) * | 2020-02-28 | 2024-04-19 | 台湾粒线体应用技术股份有限公司 | 线粒体的冷冻保存剂与使用其的线粒体冷冻保存方法 |
| CN113549653B (zh) * | 2020-04-23 | 2024-03-22 | 上海赛比曼生物科技有限公司 | 用于慢病毒载体长期存贮的组合试剂 |
| CN111588859B (zh) * | 2020-06-02 | 2021-09-03 | 成都可恩生物科技有限公司 | 一种冻干保护剂及其应用和冻干苗及其制备方法 |
| CN112501024A (zh) * | 2020-12-03 | 2021-03-16 | 英科新创（苏州）生物科技有限公司 | 一种体外诊断试剂盒通用型质控品保存液 |
| EP4012025A1 (en) * | 2020-12-10 | 2022-06-15 | Univerzita Palackého v Olomouci | Transport medium for samples containing nucleic acids and/or proteins |
| CN113730592B (zh) * | 2021-09-03 | 2023-12-19 | 吉林正业生物制品股份有限公司 | 一种鸭坦布苏病毒病活疫苗冻干保护剂及制备方法和应用 |
| WO2023158989A1 (en) * | 2022-02-15 | 2023-08-24 | Takeda Vaccines, Inc. | Dengue vaccine batch mixing process |
| AU2023365824A1 (en) * | 2022-10-18 | 2025-06-05 | Takeda Vaccines, Inc. | Dengue vaccine formulation |
| WO2025027616A1 (en) * | 2023-08-01 | 2025-02-06 | Serum Institute Of India Private Limited | Freeze-dried viral vaccine compositions and method of manufacturing thereof |
| WO2025072259A1 (en) | 2023-09-25 | 2025-04-03 | Takeda Vaccines, Inc. | Coadministration of tetravalent dengue vaccine with hpv vaccine |
| WO2025122946A1 (en) * | 2023-12-07 | 2025-06-12 | Rovin Richard A | Zika viruses and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005066333A1 (en) * | 2003-12-30 | 2005-07-21 | Aventis Pasteur, Inc. | Stabilizing compositions for recombinant viruses |
| CA2668834C (en) | 2006-11-07 | 2016-10-11 | Sanofi Pasteur Biologics Co. | Stabilization of vaccines by lyophilization |
| SI2144998T1 (sl) * | 2007-04-06 | 2017-05-31 | Takeda Vaccines, Inc. | Postopki in sestavki za žive atenuirane viruse |
| EP2143440A1 (fr) * | 2008-07-09 | 2010-01-13 | Sanofi Pasteur | Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués |
| CN104984357B (zh) * | 2015-06-02 | 2018-01-30 | 长春百克生物科技股份公司 | 不含明胶的疫苗保护剂组合物及流感减毒活疫苗 |
| EP3442571A1 (en) * | 2016-04-13 | 2019-02-20 | Takeda Vaccines, Inc. | Compositions and methods of vaccination against dengue virus in children and young adults |
-
2017
- 2017-08-02 TW TW111118644A patent/TW202309276A/zh unknown
- 2017-08-02 TW TW106126119A patent/TWI766876B/zh active
- 2017-08-03 MX MX2019001473A patent/MX2019001473A/es unknown
- 2017-08-03 SG SG11201811831SA patent/SG11201811831SA/en unknown
- 2017-08-03 CA CA3030343A patent/CA3030343A1/en active Pending
- 2017-08-03 SG SG10201913040SA patent/SG10201913040SA/en unknown
- 2017-08-03 WO PCT/US2017/045375 patent/WO2018027075A1/en not_active Ceased
- 2017-08-03 AU AU2017305498A patent/AU2017305498B2/en active Active
- 2017-08-03 KR KR1020237030300A patent/KR20230132887A/ko not_active Withdrawn
- 2017-08-03 US US16/322,791 patent/US10835597B2/en active Active
- 2017-08-03 CN CN201780047777.5A patent/CN109789200A/zh active Pending
- 2017-08-03 KR KR1020197005623A patent/KR102576789B1/ko active Active
- 2017-08-03 EP EP17751959.2A patent/EP3493839A1/en active Pending
- 2017-08-03 JP JP2019505214A patent/JP7280179B2/ja active Active
-
2019
- 2019-01-03 PH PH12019500003A patent/PH12019500003A1/en unknown
- 2019-02-01 MX MX2022010907A patent/MX2022010907A/es unknown
- 2019-02-19 CO CONC2019/0001448A patent/CO2019001448A2/es unknown
-
2020
- 2020-10-05 US US17/062,923 patent/US11701421B2/en active Active
-
2023
- 2023-01-25 JP JP2023009386A patent/JP2023052624A/ja active Pending
- 2023-02-23 US US18/113,193 patent/US20230263880A1/en active Pending
- 2023-06-14 AU AU2023203715A patent/AU2023203715A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018027075A1 (en) | 2018-02-08 |
| JP2019524771A (ja) | 2019-09-05 |
| US10835597B2 (en) | 2020-11-17 |
| US11701421B2 (en) | 2023-07-18 |
| KR20230132887A (ko) | 2023-09-18 |
| JP7280179B2 (ja) | 2023-05-23 |
| MX2019001473A (es) | 2019-09-23 |
| PH12019500003A1 (en) | 2019-10-14 |
| TWI766876B (zh) | 2022-06-11 |
| TW202309276A (zh) | 2023-03-01 |
| SG10201913040SA (en) | 2020-03-30 |
| CA3030343A1 (en) | 2018-02-08 |
| US20230263880A1 (en) | 2023-08-24 |
| AU2017305498B2 (en) | 2023-03-30 |
| AU2017305498A1 (en) | 2019-01-24 |
| JP2023052624A (ja) | 2023-04-11 |
| TW201807191A (zh) | 2018-03-01 |
| KR20190034598A (ko) | 2019-04-02 |
| CN109789200A (zh) | 2019-05-21 |
| KR102576789B1 (ko) | 2023-09-12 |
| MX2022010907A (es) | 2022-10-07 |
| US20210121558A1 (en) | 2021-04-29 |
| AU2023203715A1 (en) | 2023-07-06 |
| CO2019001448A2 (es) | 2019-04-30 |
| EP3493839A1 (en) | 2019-06-12 |
| BR112019001299A2 (pt) | 2019-04-30 |
| US20190184004A1 (en) | 2019-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908604YA (en) | Fused imidazo-piperidine jak inhibitor compound | |
| SG11201803073TA (en) | Insect singulator system | |
| SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
| SG11201907891XA (en) | Combination therapy for the treatment or prevention of tumours | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
| SG11201808799SA (en) | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors | |
| SG11201807003UA (en) | Smc combination therapy for the treatment of cancer | |
| SG11201900028VA (en) | Crispr/cas9-based compositions and methods for treating cancer | |
| SG11201803906PA (en) | Control of cellular redox levels | |
| SG11201906431UA (en) | Method for the treatment of thromboembolism | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201902988UA (en) | Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof | |
| SG11201909825VA (en) | Hsp90 inhibitor oral formulations and related methods | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201811074RA (en) | Nant cancer vaccine | |
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201810951RA (en) | Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy | |
| SG11201810793XA (en) | Pharmaceutical combinations | |
| SG11201805368YA (en) | Anthelmintic depsipeptide compounds | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
| SG11202000263QA (en) | Immunomodulatory retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | |
| SG11201903431SA (en) | Sstr-targeted conjugates and particles and formulations thereof | |
| SG11201804220SA (en) | Activated stem cells and systemic treatment methods for infected wounds |